ROIV · earnings call history
Roivant Q1 FY27 — Brepocitinib DM Launch Imminent, Robust Pipeline Catalysts Ahead
Read the briefRoivant Q4 FY26 — Strong Clinical Data & Financial Position
Read the briefBrowse all US companies on the earnings-call register.